NCT lookup

Inclusion Criteria:

* Pathologically documented metastatic non-squamous NSCLC.
* Has relapsed from or is refractory to at least one-line of anticancer treatment.
* Documented HER2 exon 19 or 20 mutation from central FFPE tumour tissue testing.
* WHO or ECOG performance status of 0 or 1.
* Presence of at least one measurable lesion assessed by the investigator based on RECIST 1.1.
* LVEF ≥ 50% within 28 days before enrolment.

Exclusion Criteria:

* Mixed small cell lung cancer, squamous histology NSCLC, and sarcomatoid histology variant NSCLC.
* Corrected QT interval (QTcF) prolongation to \> 470 ms (females) or \> 450 ms (males), based on average of the screening triplicate 12-lead ECG.
* History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
* Has unresolved toxicities from previous anticancer therapy, defined as toxicities (excluding alopecia) not yet resolved to Grade ≤1 or baseline. Participants with clinically stable chronic Grade 2 toxicity not reasonably expected to be exacerbated by study intervention may be included only after consultation with the AstraZeneca study physician or designee.
* Has been previously treated with HER2-targeted therapies, except for pan-HER class TKIs or has received prior treatment with an ADC which consists of an exatecan derivative that is a topoisomerase I inhibitor.

• Baoding, China
• Beijing, China
• Beijing, China
• Changchun, China
• Changsha, China
• Changsha, China
• Chengdu, China
• Chongqing, China
• Guangzhou, China
• Guangzhou, China
• Hangzhou, China
• Hangzhou, China
• Harbin, China
• Hefei, China
• Hefei, China
• Linyi, China
• Nanjing, China
• Shandong, China
• Shanghai, China
• Shanghai, China
• Shenyang, China
• Shenzhen, China
• Wuhan, China
• Wuhan, China
• Xi'an, China
• Xiamen, China
• Yangzhou, China
• Zhengzhou, China